Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

Y0000557

Fluconazole

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C13H12F2N6O
Número CAS:
86386-73-4
Peso molecular:
306.27
Número MDL:
MFCD00274549
Código UNSPSC:
41116107
ID de substância PubChem:
329831019
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

fluconazole

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

chave InChI

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Fluconazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1271700

Fluconazole, United States Pharmacopeia (USP) Reference Standard

Y0000558

Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0000574

Fluconazole impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000573

Fluconazole impurity B, European Pharmacopoeia (EP) Reference Standard

1271733

Fluconazole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1271722

Fluconazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1271711

Fluconazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1651

Fluconazole Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1826

Fluconazole Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1862

Fluconazole Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2037

Fluconazole Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

BP1174

Fluconazole, British Pharmacopoeia (BP) Reference Standard

BP1175

Fluconazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2048

Fluconazole Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2046

Fluconazole Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1900

Fluconazole Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9026

1,2,4-Triazole, reference material

PHR9031

2-(2,4-Difluorophenyl)-1,2,3-propanetriol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Pictogramas

Health hazardExclamation mark
GHS08,GHS07

Palavra indicadora

Danger

Frases de perigo

H302,H360D,H362,H412

Classificações de perigo

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 8

1 of 8

vibrant-m

Y0001361

Amphotericin B for microbiological assay

Voriconazole European Pharmacopoeia (EP) Reference Standard

Y0001395

Voriconazole

Itraconazole ≥98% (HPLC)

Sigma-Aldrich

I6657

Itraconazole

Caspofungin diacetate ≥97% (HPLC)

Sigma-Aldrich

SML0425

Caspofungin diacetate

vibrant-m

M1880000

Miconazole

Itraconazole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1834

Itraconazole

Voriconazole ≥98% (HPLC)

Sigma-Aldrich

PZ0005

Voriconazole

Voriconazole Pharmaceutical Secondary Standard: Certified Reference Material

Supelco

PHR1892

Voriconazole

Marcio Nucci et al.
PloS one, 8(3), e59373-e59373 (2013-03-26)
The epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America. We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were
A-C L Meyer et al.
Tropical medicine & international health : TM & IH, 18(4), 495-503 (2013-02-02)
To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100
Jana Bogum et al.
Journal of the American Society of Nephrology : JASN, 24(5), 744-758 (2013-04-06)
In the principal cells of the renal collecting duct, arginine vasopressin (AVP) stimulates the synthesis of cAMP, leading to signaling events that culminate in the phosphorylation of aquaporin-2 water channels and their redistribution from intracellular domains to the plasma membrane
Nicholas G Wysham et al.
Chest, 143(5), 1478-1479 (2013-05-08)
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica